Jesup & Lamont initiates coverage on RTI Biologics (NASDAQ: RTIX) with a Buy rating and a $12 price target.
...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE